Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

99.25
+9.7510.89%
Post-market: 99.250.00000.00%19:55 EDT
Volume:1.72M
Turnover:167.99M
Market Cap:6.41B
PE:-92.99
High:99.78
Open:91.14
Low:90.02
Close:89.50
Loading ...

Blueprint Medicines Corp. Reports Strong Earnings Growth

TIPRANKS
·
1 hour ago

Positive Outlook for Blueprint Medicines Driven by Strong Ayvakit Performance and Pipeline Progress

TIPRANKS
·
7 hours ago

Stock Track | Blueprint Medicines Soars 5.06% as Q1 Results Beat Expectations and Company Raises Full-Year Guidance

Stock Track
·
Yesterday

Blueprint Medicines' Q1 Earnings Decline, Revenue Increases

MT Newswires Live
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Blueprint Medicines (BPMC) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Yesterday

Blueprint Medicines Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Yesterday

Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

Zacks
·
Yesterday

Blueprint Medicines: Strong Financial Performance and Strategic Initiatives Justify Buy Rating

TIPRANKS
·
Yesterday

Earnings Flash (BPMC) Blueprint Medicines Posts Q1 EPS of $0.01, vs. FactSet Est of $-0.49 Loss per Share

MT Newswires Live
·
Yesterday

Blueprint Medicines Q1 EPS $0.01 Beats $(0.56) Estimate, Sales $149.40M Miss $155.45M Estimate

Benzinga
·
Yesterday

BRIEF-Blueprint Medicines Q1 Net Income USD 496 Thousand Vs. IBES Estimate USD -35.6 Million

Reuters
·
Yesterday

Blueprint Medicines Q1 Basic EPS USD 0.01

THOMSON REUTERS
·
Yesterday

Blueprint Medicines Reports First Quarter 2025 Results and Raises Ayvakit®/Ayvakyt® (Avapritinib) Full Year Revenue Guidance

THOMSON REUTERS
·
Yesterday

Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance

PR Newswire
·
Yesterday

Blueprint Medicines Corp expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
29 Apr

Blueprint Medicines Is Maintained at Buy by Needham

Dow Jones
·
29 Apr

Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

Zacks
·
24 Apr

Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying

Insider Monkey
·
24 Apr

3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
22 Apr

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC)

TIPRANKS
·
17 Apr